Modulation of Innate Immunity by G-CSF and Inflammatory Response by LBPK95A Improves the Outcome of Sepsis in a Rat Model

Figure 1

Modulation of inflammatory severity using various LBPK95A doses improved the therapeutic effect of G-CSF after septic insult. (a) Rats in the control group (control, injection of human stool suspension), G-CSF group (G-CSF, treatment with G-CSF for 5 days before septic insult), 1% Combi group (1% Combi group, G-CSF pretreatment for 5 days, 0.05 mg/kg LBPK95A injection immediately after injection of human stool suspension), 10% Combi group (10% Combi group G-CSF pretreatment for 5 days, 0.5 mg/kg LBPK95A injection immediately after injection of human stool suspension), and 100% Combi group (100% Combi group, G-CSF pretreatment for 5 days, 5 mg/kg LBPK95A injection immediately after injection of human stool suspension) were monitored every 3 h for 72 hours to record the activity and survival rate. . Gray line: data were collected from a previous study [14]. (b) Morphological evaluations of hepatic injury (left part) and kidney injury (right part) from all 5 groups at 12 h after septic insult. Hematoxylin and eosin staining, original magnification ×400. Black arrow: neutrophil infiltration, blue arrow: erythrocyte congestion, red arrow: hepatic necrosis, purple arrow: sinusoid dilatation, gray arrow: pulmonary edema. Hematoxylin and eosin staining, original magnification ×400.

(a)

(b)